Pharmamar.com users come from these countries:
50.0% Germany 50.0% OTHER
Genomica SAU consigue la Patente : ASSAY FOR DIAGNOSING A PREDISPOSITION TO PATHOLOGICAL BONE CONDITIONS AND ANTICIPATING RESPONSE TO TREATMENT .
Publication number: EP2046987 (A2)
Publication date: 2009-04-15
Inventor(s): VILLAHERMOSA JAEN MARIA LUISA [ES]; MORAGA ANA I [ES]
Applicant(s): GENOMICA S A U [ES]
Methods and kits are provided for detection of specific polymorphisms that predispose towards osteoporosis and/or are indicative of likely response to treatment. Particular genes analysed are i) calcitonin Receptor; Vitamin D Receptor; Estrogen Receptor; Collagen I A1; and/or ii) Osteoprotegerin, LRP5, CYP17, CYP19 and MTHFR genes. The two groups may be analysed in separate multiplex amplification reactions on a sample.
Publication date: 2009-04-15
Inventor(s): VILLAHERMOSA JAEN MARIA LUISA [ES]; MORAGA ANA I [ES]
Applicant(s): GENOMICA S A U [ES]
Methods and kits are provided for detection of specific polymorphisms that predispose towards osteoporosis and/or are indicative of likely response to treatment. Particular genes analysed are i) calcitonin Receptor; Vitamin D Receptor; Estrogen Receptor; Collagen I A1; and/or ii) Osteoprotegerin, LRP5, CYP17, CYP19 and MTHFR genes. The two groups may be analysed in separate multiplex amplification reactions on a sample.
Sylentis consigue Patente US : Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure .
Publication number: US2009099113 (A1)
Publication date: 2009-04-16
Inventor(s): JIMENEZ ANA I [ES]; SESTO ANGELA [ES]; GASCON IRENE [ES]; ROMAN JOSE P [ES]; GONZALEZ DE BUITRAGO GONZALO [ES]
Applicant(s): SYLENTIS S A U [ES]
The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.
Irvalec Inicia Fase I - II en Tumores Solidos junto con el Tarceva de Roche / Genentech en New York y Barcelona .
Ensayo que ya se comunico el 30-12-2008 ... pero que recien ha iniciado el recibo de Pacientes ... Que lo lleve el Dr. Rafael Rosell uno de los mejores Oncologos del Mundo en Cancer de Pulmón ... ya es de entrada una buena Noticia . La combinación de Irvalec con Tarceva ha demostrado un gran sinergismo en modelos preclínicos incluso en líneas celulares resistentes de cáncer de pulmón no microcítico (NSCLC).Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors .
This study is currently recruiting participants.
Verified by PharmaMar, April 2009
First Received: April 16, 2009 Last Updated: April 20, 2009 History of Changes
Sponsored by: PharmaMar
Information provided by: PharmaMar
ClinicalTrials.gov Identifier: NCT00884845
Aplidin en Combinacion del Cytarabine ( ARA C ) De Pzifer . Se da por Terminada la Fase I-II en Relapsed/Refractory Leukemia .
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia .
This study has been terminated.
( Poor recruitment )
First Received: October 24, 2008 Last Updated: April 20, 2009 History of Changes
Sponsored by: PharmaMar
Information provided by: PharmaMar
ClinicalTrials.gov Identifier: NCT00780143
This study has been terminated.
( Poor recruitment )
First Received: October 24, 2008 Last Updated: April 20, 2009 History of Changes
Sponsored by: PharmaMar
Information provided by: PharmaMar
ClinicalTrials.gov Identifier: NCT00780143
Noscira útiliza Herramientas Toxicogenomicas en la I + D a la hora de saber si un Farmaco sera viable su Desarrollo Clinico .
Es tan alto el coste de los ensayos clinicos de todo Farmaco , que es importantisimo el poder saber antes de iniciar los ensayos sus posibles Efectos Toxicos , posibles Adversidades , Dosis , Frecuencias ... para poder determinar una acertada decisión y un gran ahorro de Cash .
Dendreon , una Bio que anuncia mejores Resultados Oncologicos con Prevenge en Cancer de Prostata y sube de 2,55 a 22 $$ en dias tan solo .
más imfo :
http://www.ellibrepensador.com/2009/04/19/un-experto-cree-que-la-vacuna-contra-el-cancer-de-prostata-llegara-en-dos-anos/
http://www.ellibrepensador.com/2009/04/19/un-experto-cree-que-la-vacuna-contra-el-cancer-de-prostata-llegara-en-dos-anos/